welcome Welcome

“May all be happy, may all be healed, may all be at peace and may no one ever suffer."


Loading...

Bevacizumab

100mg / 4ml
Targeted Cancer Therapy
0.00 (0)


Action Period: ...

Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.


Generic for Diseases

Generic Indications
  • Age-related macular degeneration (AMD)
  • Breast cancers and glioblastoma multiforme of the brain
  • Breast carcinoma
  • Carcinoma
  • Carcinoma of the colon
  • Colorectal cancer
  • Cystoid macular edema
  • Endometrium cancer
  • Gastric cancer
  • Kidney cancer
  • Lung carcinoma
  • Non-small cell lung cancer
  • Ovarian carcinoma
  • Renal cancers
  • Renal cell carcinoma
  • Wet ARMD

Complement Generics
Similar Generics
Inimical Generics

Component

Drug Indications

Bevacizumab is indiated for-

  • Metastatic Colorectal Cancer (mCRC)
  • Non-Squamous Non–Small Cell Lung Cancer (NSCLC)
  • Glioblastoma
  • Metastatic Renal Cell Carcinoma (mRCC)
  • Persistent, Recurrent, or Metastatic Carcinoma of the Cervix
  • Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Dosage Administration

Metastatic Colorectal Cancer (mCRC): The recommended doses are 5 mg/kg or 10 mg/kg every 2 weeks when used in combination with intravenous 5-FU-based chemotherapy.

  • Administer 5 mg/kg when used in combination with bolus-IFL.
  • Administer 10 mg/kg when used in combination with FOLFOX4.
  • Administer 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks when used in combination with a fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy regimen in patients who have progressed on a first-line Bevacizumab-containing regimen.

Non-Squamous Non-Small Cell Lung Cancer (NSCLC): The recommended dose is 15 mg/kg every 3 weeks in combination with carboplatin and paclitaxel.

Glioblastoma: The recommended dose is 10 mg/kg every 2 weeks.

Metastatic Renal Cell Carcinoma (mRCC): The recommended dose is 10 mg/kg every 2 weeks in combination with interferon alfa.

Cervical Cancer: The recommended dose of Bevacizumab is 15 mg/kg every 3 weeks as an intravenous infusion administered in combination with one of the following chemotherapy regimens: paclitaxel and cisplatin, or paclitaxel and topotecan.

Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: The recommended dose is 10mg/ kg every 2 weeks in combination with one of the following intravenous chemotherapy regimens: paclitaxel, pegylated liposomal doxorubicin, or topotecan (weekly); or 15 mg/kg every 3 weeks in combination with topotecan (every 3 weeks).

Administration

Do not administer as an intravenous push or bolus. Administer only as an intravenous (IV) infusion. Do not initiate Bevacizumab until at least 28 days following major surgery. Administer Bevacizumab after the surgical incision has fully healed.

First infusion: Administer infusion over 90 minutes. Subsequent infusions: Administer second infusion over 60 minutes if first infusion is tolerated; administer all subsequent infusions over 30 minutes if infusion over 60 minutes is tolerated.


Contraindication

There are no contraindications listed in the manufacturer’s labeling.


Side Effect

dry mouth, cough, voice changes, loss of appetite, diarrhea, nausea, vomiting, constipation, loss of appetite, mouth sores, headache, back , pain, cold symptoms (stuffy nose, sneezing, sore throat), dry or watery eyes, dry or flaky skin, hair loss, changes in your sense of taste, jaw pain/swelling/numbness, loose teeth, or gum infection.

Overdose Effects

The highest dose tested in humans (20 mg/kg IV) was associated with headache in nine of 16 patients and with severe headache in three of 16 patients.


Precaution Warning

Arterial Thromboembolic Events. Among patients receiving Bevacizumab in combination with chemotherapy, the risk of developing ATE during therapy was increased in patients with a history of arterial thromboembolism, diabetes, or age greater than 65

Use in Special Populations

The safety, effectiveness and pharmacokinetic profile of Bevacizumab in pediatric patients have not been established. In published literature reports, cases of non-mandibular osteonecrosis have been observed in patients under the age of 18 years who have received Bevacizumab. Bevacizumab is not approved for use in patients under the age of 18 years.

Antitumor activity was not observed among eight children with relapsed glioblastoma treated with Bevacizumab and irinotecan. There is insufficient information to determine the safety and efficacy of Bevacizumab in children with glioblastoma.

Pregnancy & Lactation

Pregnancy Category C. There are no adequate or well controlled studies of bevacizumab in pregnant women. It is not known whether Avastin is secreted in human milk.





Store

Bevacizumab

There is a list and complete profile of all allopathic generics available in the country where users can make various comments and give ratings. Generic similar to a generic, antagonistic generic, generic instructions, dosage administration, directions, side effects, warnings, ingredients, etc. have been added.

...
Cefotaxime
Antimicrobial drugs
...
Hyoscine Butylbromide
Gastrointestinal System Drugs
...
Citalopram Hydrobromide
Central Nervous System Drugs
...
Mifepristone + Misoprostol
Genitourinary System Drugs
...
Risperidone (Injection)
Central Nervous System Drugs
...
Dexlansoprazole
Gastrointestinal System Drugs
...
Roflumilast
Respiratory system drugs
...
Hydrogen peroxide
Antibacterial and antiviral

Searching Keywords Idea
...

Bangladesh is Number One in Digital Medical Management.
To be happy, beautiful, healthy, wealthy, hale and long-lived stay with DM3S.